ЛУКАКС Николас У. (US),ДОЛГАЧЁВ Владислав А. (US),КУНКЕЛЬ Стивен Л. (US),ХОГАБОУМ Кори М. (US),ФЭН Сэм Х. (US)
申请号：
RU2013131825/10
公开号：
RU2013131825A
申请日:
2012.01.10
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A method of treating a fibrotic disease or tissue remodeling disease, comprising administering a therapeutically effective amount of a stem cell factor inhibitor to a subject with or having a risk of tissue remodeling associated with tissue remodeling. The method according to claim 1, characterized in that the inhibitor is an isolated antibody or antigen-binding fragment thereof. The method according to claim 1, characterized in that the introduction prevents or reduces the severity of at least one symptom of the disease. The method according to claim 2, characterized in that the antibody is a monoclonal antibody or antigen-binding fragment thereof. The method according to claim 2, characterized in that the antibody or its antigen binding fragment specifically binds to a stem cell factor. The method of claim 2, wherein the antibody or antigen binding fragment thereof specifically binds to a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 8.7. The method of claim 2, wherein the antibody is a polyclonal antibody. The method according to claim 1, characterized in that the inhibitor is a small interfering RNA. The method according to claim 1, characterized in that the subject has an abnormal activity of a stem cell factor. The method according to claim 1, characterized in that the subject has an abnormal production of collagen. The method according to claim 1, characterized in that the disease is fibrosis. The method according to claim 1, wherein the disease is a remodeling disease. The method of claim 1, wherein the disease is a lung disease. Way1. Способ лечения фиброзного заболевания или заболевания ремоделирования ткани, включающий введение терапевтически эффективного количества ингибитора фактора стволовых клеток субъекту с фиброзным заболеванием или заболеванием, связанным с ремоделированием ткани, или имеющему риск развития таких заболеваний.2. Способ по п.1, отличающийся тем, что ингибитор является в
